Redefining Treatment Paradigms With Botensilimab and Balstilimab for mCRC
By Marwan G. Fakih, MD - Last Updated: January 31, 2025Dr. Marwan Fakih of City of Hope continues his discussion on the phase 2 study of botensilimab with balstilimab for the treatment of refractory microsatellite stable metastatic colorectal cancer with no liver metastases that was presented at ASCO GI 2025.
Advertisement
Dr. Fakih elaborates on the combination’s objective response rate, and how the treatment can potentially redefine treatment paradigms in the future.
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.